AIM:To confirm the value of blocking treatment byzenshengping(ZSP),a Chinese herb composite,andRiboflavin for esophageal epithelia dysplasia cases screenedout in high risk area in northern china by exfollative ballooncytology(EBC),so to reduce the incidence rate ofesophageal cancer(EC).METHODS:Esophageal epithelium dysplasia cases includingmind esophageal epithelium dysplasia(MEED),stage onesevere esophageal epithelium dysplasia(SEED Ⅰ),andstage two severe esophageal epithelium dysplasia(SEED Ⅱ)were screened out from people aged 40 years and older inthe high risk area of Chixian.These cases were randomlydivided into a treatment and control group.Subjects in thetreatment and control groups took ZSP,riboflavin,andplacebo daily for three years.EC cases registered by cancerregistry and identified by EBC re-screening in the treatmentand control groups were used to calculate incidence andblocking rates to demonstrate the effects of blockingmedication.RESULTS:It was found that 31.92% and 24.15% of peopleaged 40 years and older in Cixian could been diagnosed asMEED and SEED cases.The severity of dysplasia increasedwith age.ZSP had blocked EC occurrence by 47.79% after 3year medication among the SEED cases.CONCLUSION:ZSP can block the development from SEED Ⅰand SEED Ⅱ to EC by 47.79%.Efforts should be made toscreen and treat dysplasia cases in people aged 40 years andolder in high risk areas to reduce the mortality figures. AIM: To confirm the value of blocking treatment byzenshengping (ZSP), a Chinese herb composite, and Riboflavin for esophageal epithelia dysplasia cases screened out in high risk area in northern china by exfoliated ballooncytology (EBC), so to reduce the incidence rate of esophageal cancer (EC ) .METHODS: Esophageal epithelium dysplasia cases including mind esophageal epithelium dysplasia (MEED), stage onesevere esophageal epithelium dysplasia (SEED Ⅰ), and staging two severe esophageal epithelium dysplasia (SEED Ⅱ) were screened out from people aged 40 years and older inthe high risk area of Chixian.These cases were randomlydivided into a treatment and control group.Subjects in the treatment and control groups took ZSP, riboflavin, andplacebo daily for three years. EC cases registered by cancerregistry and identified by EBC re-screening in the treatment and control groups were used to calculate incidence andblocking rates to demonstrate the effects of blockingmedication.RESULTS: It was found that 31.92% and 24.15% of peopleaged 40 years and older in Cixian could been diagnosed asMEED and SEED cases.The severity of dysplasia increasedwith age. ZSP had blocked EC occurrence by 47.79% after 3year Ⅰand SEED Ⅱ to EC by 47.79% .Efforts should be made toscreen and treat dysplasia cases in people aged 40 years andolder in high risk areas to reduce the mortality figures.